| Literature DB >> 31963130 |
Ingars Reinholds1,2, Janis Rusko1,2, Iveta Pugajeva1, Zane Berzina1,2, Martins Jansons1,2, Olga Kirilina-Gutmane1, Kristina Tihomirova1,3, Vadims Bartkevics1,2.
Abstract
The occurrence and dietary exposureEntities:
Keywords: HPLC-MS/MS; HPLC-PAD; ICP-MS; biogenic amines; blue cheese; deterministic modelling; dietary exposure; hazard index; heavy metals; mycotoxins
Year: 2020 PMID: 31963130 PMCID: PMC7023506 DOI: 10.3390/foods9010093
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Instrumental parameters of LC-MS/MS method.
| Mycotoxin | RT (min) | Precursor ( | MRM1 ( | CE1 ( | MRM2 ( | CE2 ( | MRM3 ( | CE3 ( |
|---|---|---|---|---|---|---|---|---|
| PA | 1.0 | 171.1 | 125.0 | 13 | 153.0 | 10 | − | − |
| AFM1 | 1.4 | 329.1 | 229.0 | 44 | 273.1 | 22 | − | − |
| ROQ C | 2.2 | 391.0 | 193.1 | 23 | 323.1 | 18 | − | − |
| AFB1 | 2.5 | 313.0 | 240.9 | 39 | 285.0 | 22 | − | − |
| MPA | 5.0 | 319.0 | 191.0 | 18 | 205.0 | 16 | − | − |
| OTB | 5.4 | 370.1 | 103.1 | 30 | 205.0 | 20 | − | − |
| CVD | 6.1 | 420.4 | 285.2 | 14 | 315.1 | 10 | − | − |
| SBL | 6.5 | 386.3 | 122.1 | 55 | 150.0 | 55 | 178.0 | 40 |
| OTA | 6.5 | 404.0 | 239.0 | 22 | 358.0 | 15 | − | − |
| CIT | 7.2 | 251.1 | 191.1 | 16 | 205.1 | 15 | − | − |
| PNA | 7.9 | 634.4 | 558.5 | 20 | 616.4 | 12 | − | − |
| ENN B | 8.3 | 657.4 | 196.0 | 32 | 214.0 | 34 | − | − |
| ENN B1 | 8.5 | 671.3 | 196.0 | 34 | 214.0 | 35 | − | − |
| BEA | 8.5 | 802.7 | 244.1 | 25 | 785.3 | 20 | − | − |
| ENN A | 8.6 | 685.2 | 210.0 | 31 | 228.0 | 33 | − | − |
| ENN A1 | 8.8 | 699.4 | 210.0 | 34 | 228.0 | 35 | − | − |
RT—retention time; MRM1: quantifier transition; MRM2, MRM3: qualifier transitions; CE: collision energy.
Instrumental parameters of ICP-MS method.
| Parameter | Value |
|---|---|
| Plasma mode | normal, robust |
| RF power (kW) | 1.30 |
| Sampling depth (mm) | 8.0 |
| Carrier gas flow (L min−1) | 0.6 |
| Dilution gas flow (L min−1) | 0.4 |
| Spray chamber temperature (°C) | 2.0 |
| Extraction lens l (V) | 0 |
| Kinetic energy discrimination (V) | 3 |
| Scanning mode | Peak hopping |
Figure 1Representative chromatograms of biogenic amines in a blank sample spiked with standard mixture at 75 mg kg−1 concentration.
The concentrations of mycotoxins found in blue cheese samples.
| Country | ROQ-C (µg kg−1) | MPA (µg kg−1) | AFM1 (µg kg−1) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases | Mean | Range | Cases | Mean | Range | Cases | Mean | Range | |
| Italy | 11/11 | 836 | 144–2542 | 6/11 | 10.9 | 9.4–15.7 | 3/11 | 0.03 | 0.02–0.05 |
| France | 9/9 | 396 | 3.2–718 | 5/9 | 156 | 9.5–208 | − | − | − |
| Poland | 7/7 | 439 | 5.3–790 | 2/7 | 7.7 | 5.8–9.5 | − | − | − |
| Denmark | 7/7 | 1051 | 209–2150 | 7/7 | 208 | 9.7–599 | − | − | − |
| England | 3/3 | 3675 | 2077–5454 | 1/3 | − | 9.6 | − | − | − |
| Latvia | 3/3 | 620 | 101–1323 | 3/3 | 23.9 | 10.7–41.3 | − | − | − |
| Spain | 2/2 | 138 | 111–165 | 2/2 | 108 | 91–125 | − | − | − |
| Lithuania | 2/2 | 352 | 156–547 | 1/2 | − | 179 | − | − | − |
| Germany | 2/2 | 992 | 507–1476 | 2/2 | 20.8 | 9.7–31.8 | − | − | − |
The concentrations of biogenic amines found in blue cheese samples.
| Biogenic Amine (BA) | Cases (Total %) | Uncontaminated Samples ( | Mean Concentration (mg kg−1) | Concentration Range (mg kg−1) |
|---|---|---|---|---|
| Tyramine | 58.7 | 27 | 70.7 | 1.1–717 |
| Tryptamine | 47.8 | 22 | 30.4 | 1.2–213 |
| Putrescine | 52.2 | 24 | 9.3 | 1.3–45.5 |
| Phenethylamine | 84.8 | 39 | 10 | 1.5–43.9 |
| Cadaverine | 47.8 | 22 | 22.1 | 1.7–131 |
| Histamine | 69.6 | 32 | 23.3 | 0.2–186 |
Figure 2The relative distribution of blue mould cheese contamination with biogenic amines (count of positive samples for each biogenic amine is shown above each bar diagram.
The concentrations of heavy metals found in blue cheese samples.
| Heavy Metal | Cases (Total %) | Samples (n) | Mean Concentration (mg kg−1) | Concentration Range (mg kg−1) |
|---|---|---|---|---|
| Al | 40.9 | 18/44 | 0.55 | 0.33–1.11 |
| Mn | 86 | 38/44 | 0.16 | 0.083–0.63 |
| Fe | 52.2 | 14/44 | 2.68 | 1.57–12.4 |
| Zn | 100 | 44/44 | 27.3 | 10.4–39.5 |
| Se | 100 | 44/44 | 0.11 | 0.035–0.29 |
| Cd | 2.3 | 1/44 | 0.002 | 0.002 |
| Sn | 29.5 | 13/44 | 2.59 | 0.024–32.5 |
| Pb | 56.8 | 25/44 | 0.013 | 0.007–0.024 |
Hazard indices for chronic dietary exposure to heavy metals from blue cheese.
|
|
|
|
|
|
|
|
|
|
|
| HI average consumers | 0.01 | 0.01 | 0.01 | 0.00 | 0.04 | 0.03 | 0.04 | 0.05 | 0.03 |
| HI high consumers | 0.02 | 0.01 | 0.02 | 0.01 | 0.11 | 0.07 | 0.09 | 0.14 | 0.06 |
|
|
|
|
|
|
|
|
|
|
|
| HI average consumers | 0.05 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.01 |
| HI high consumers | 0.10 | 0.07 | 0.08 | 0.07 | 0.10 | 0.08 | 0.09 | 0.09 | 0.03 |
Hazard indices for chronic dietary exposure to biogenic amines from blue cheese.
|
|
|
|
|
|
|
|
|
|
| HI average consumers | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| HI high consumers | 0.08 | 0.06 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.05 |
| HI high consumers, 95th percentile occurrence data | 0.48 | 0.36 | 0.13 | 0.11 | 0.12 | 0.09 | 0.11 | 0.28 |
|
|
|
|
|
|
|
|
|
|
| HI average consumers | 0.02 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.05 | 0.05 |
| HI high consumers | 0.04 | 0.11 | 0.12 | 0.10 | 0.10 | 0.09 | 0.10 | 0.10 |
| HI high consumers, 95th percentile occurrence data | 0.27 | 0.66 | 0.77 | 0.63 | 0.64 | 0.55 | 0.59 | 0.59 |
Acute dietary exposure to biogenic amines and Roquefortine C (RoQ C) from blue cheese, as percentage of aRfD values.
| Country, Population and Survey Year | Tyr | Try | Put | Phe | Cad | His | ROQ C | Tyr | Try | Put | Phe | Cad | His | ROQ C | Tyr | Try | Put | Phe | Cad | His | ROQ C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean Consumption, Mean UB Occurrence Values | High Consumption, Mean UB Occurrence Values | High Consumption, 95th Percentile Occurrence Values | |||||||||||||||||||
| DK (Infants, 2006) | 1.2% | 0.0% | 0.0% | 0.8% | 0.0% | 0.9% | 23% | 3.2% | 0.1% | 0.0% | 2.1% | 0.1% | 2.4% | 60% | 25.2% | 0.6% | 0.2% | 5.2% | 0.4% | 16.7% | 235% |
| DK (Toddlers, 2006) | 1.0% | 0.0% | 0.0% | 0.6% | 0.0% | 0.7% | 18% | 2.4% | 0.0% | 0.0% | 1.6% | 0.0% | 1.8% | 44% | 18.8% | 0.4% | 0.2% | 3.9% | 0.3% | 12.4% | 175% |
| DK (Adolescents, 2000) | 0.4% | 0.0% | 0.0% | 0.3% | 0.0% | 0.3% | 8% | 0.9% | 0.0% | 0.0% | 0.6% | 0.0% | 0.7% | 16% | 6.8% | 0.2% | 0.1% | 1.4% | 0.1% | 4.5% | 64% |
| DK (Adults, 2000) | 0.3% | 0.0% | 0.0% | 0.2% | 0.0% | 0.2% | 6% | 0.7% | 0.0% | 0.0% | 0.5% | 0.0% | 0.5% | 14% | 5.7% | 0.1% | 0.1% | 1.2% | 0.1% | 3.8% | 54% |
| DK (Adults, 2005) | 0.4% | 0.0% | 0.0% | 0.2% | 0.0% | 0.3% | 7% | 0.8% | 0.0% | 0.0% | 0.5% | 0.0% | 0.6% | 15% | 6.2% | 0.1% | 0.1% | 1.3% | 0.1% | 4.1% | 57% |
| DK (Elderly, 2000) | 0.3% | 0.0% | 0.0% | 0.2% | 0.0% | 0.2% | 5% | 0.6% | 0.0% | 0.0% | 0.4% | 0.0% | 0.5% | 11% | 4.8% | 0.1% | 0.0% | 1.0% | 0.1% | 3.2% | 45% |
| DK (Elderly, 2005) | 0.3% | 0.0% | 0.0% | 0.2% | 0.0% | 0.3% | 6% | 0.7% | 0.0% | 0.0% | 0.5% | 0.0% | 0.5% | 13% | 5.5% | 0.1% | 0.0% | 1.1% | 0.1% | 3.7% | 52% |
| FI (Adults, 2007) | 0.9% | 0.0% | 0.0% | 0.6% | 0.0% | 0.7% | 16% | 1.8% | 0.0% | 0.0% | 1.2% | 0.0% | 1.4% | 35% | 14.6% | 0.3% | 0.1% | 3.0% | 0.3% | 9.7% | 136% |
| FI (Adults, 2012) | 0.9% | 0.0% | 0.0% | 0.6% | 0.0% | 0.7% | 18% | 1.8% | 0.0% | 0.0% | 1.2% | 0.0% | 1.4% | 34% | 14.2% | 0.3% | 0.1% | 2.9% | 0.3% | 9.4% | 133% |
| FR (Adolescents, 2007) | 2.1% | 0.0% | 0.0% | 1.4% | 0.0% | 1.6% | 40% | 4.4% | 0.1% | 0.0% | 2.9% | 0.1% | 3.3% | 82% | 34.7% | 0.8% | 0.3% | 7.1% | 0.6% | 23.0% | 324% |
| FR (Adolescents, 2014) | 2.1% | 0.0% | 0.0% | 1.4% | 0.0% | 1.6% | 40% | 5.0% | 0.1% | 0.0% | 3.3% | 0.1% | 3.8% | 95% | 40.1% | 0.9% | 0.4% | 8.3% | 0.7% | 26.6% | 375% |
| FR (Adults, 2007) | 2.0% | 0.0% | 0.0% | 1.3% | 0.0% | 1.5% | 38% | 4.1% | 0.1% | 0.0% | 2.8% | 0.1% | 3.2% | 78% | 33.0% | 0.7% | 0.3% | 6.8% | 0.6% | 21.9% | 308% |
| FR (Adults, 2007) | 1.9% | 0.0% | 0.0% | 1.3% | 0.0% | 1.4% | 36% | 4.2% | 0.1% | 0.0% | 2.8% | 0.1% | 3.2% | 78% | 33.1% | 0.7% | 0.3% | 6.8% | 0.6% | 22.0% | 309% |
| FR (Adults, 2014) | 1.6% | 0.0% | 0.0% | 1.1% | 0.0% | 1.2% | 30% | 3.6% | 0.1% | 0.0% | 2.4% | 0.1% | 2.7% | 68% | 28.6% | 0.6% | 0.3% | 5.9% | 0.5% | 19.0% | 268% |
| FR (Elderly, 2007) | 1.9% | 0.0% | 0.0% | 1.3% | 0.0% | 1.4% | 36% | 3.8% | 0.1% | 0.0% | 2.6% | 0.1% | 2.9% | 73% | 30.7% | 0.7% | 0.3% | 6.3% | 0.5% | 20.3% | 286% |
| IT (Adults, 2005) | 2.2% | 0.0% | 0.0% | 1.5% | 0.0% | 1.7% | 41% | 3.9% | 0.1% | 0.0% | 2.6% | 0.1% | 3.0% | 74% | 31.0% | 0.7% | 0.3% | 6.4% | 0.5% | 20.6% | 290% |